Drug Database · Clinicians

Potassium citrate

Brands (48) Calta, K-XR, Medcit…Show all

US brand (reference label): POTASSIUM CITRATE EXTENDED RELEASE; not a Philippine-registered brand.

Antiurolithic; Anti-urolithic; and others PH FDA category

CI if GFR <0.7 mL/kg/min or CKDRx · Prescription drug61 PH productsPNF-listedVAT-exempt Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 5f38b02c-703c-4fc2-b833-654e41bd617f, version date July 1, 2025 (POTASSIUM CITRATE EXTENDED RELEASE · Strides Pharma Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Renal tubular acidosis (RTA) with calcium stones
  • Hypocitraturic calcium oxalate nephrolithiasis of any etiology
  • Uric acid lithiasis with or without calcium stones
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Potassium citrate is a citrate salt of potassium indicated for the management of:

  • Renal tubular acidosis (RTA) with calcium stones (1.1)
  • Hypocitraturic calcium oxalate nephrolithiasis of any etiology (1.2)
  • Uric acid lithiasis with or without calcium stones (1.3) 1.1 Renal Tubular Acidosis (RTA) with Calcium Stones Potassium citrate is indicated for the management of renal tubular acidosis [see Clinical Studies (14.1)]. 1.2 Hypocitraturic Calcium Oxalate Nephrolithiasis of any Etiology Potassium citrate is indicated for the management of Hypocitraturic calcium oxalate nephrolithiasis [see Clinical Studies (14.2)]. 1.3 Uric Acid Llithiasis with or without Calcium Stones Potassium citrate is indicated for the management of Uric acid lithiasis with or without calcium stones [see Clinical Studies (14.3)].

Contraindications

  • Renal insufficiency with GFR <0.7 mL/kg/min
  • Hyperkalemia or predisposing conditions (chronic renal failure, uncontrolled diabetes, acute dehydration, adrenal insufficiency, potassium-sparing drugs)
  • Delayed tablet passage (delayed gastric emptying, obstruction, anticholinergics)
  • Peptic ulcer disease
  • Active urinary tract infection
renalcarematters.com, reviewed
Contraindications (US label) US FDA label

4 CONTRAINDICATIONS Potassium citrate extended-release tablets are contraindicated:

  • In patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride).
  • In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication.
  • In patients with peptic ulcer disease because of its ulcerogenic potential.
  • In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of Potassium citrate extended–release tablets to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth.
  • In patients with renal insufficiency (glomerular filtration rate of less than 0.7 ml/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia.
  • Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown (4)
  • Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture (4)
  • Patients with peptic ulcer disease (4)
  • Patients with active urinary tract infection (4)
  • Patients with renal insufficiency (glomerular filtration rate of less than 0.7 ml/kg/min) (4)

Dosing: Adult

  • Severe hypocitraturia (urinary citrate <150 mg/day): Start 60 mEq/day in 2 or 3 doses with meals
  • Mild to moderate hypocitraturia: Start 30 mEq/day in 2 or 3 doses with meals; avoid above 100 mEq/day
renalcarematters.com, reviewed
Dosage and administration (US label) US FDA label
  • Objective: To restore normal urinary citrate (greater than 320 mg/day and as close to the normal mean of 640 mg/day as possible), and to increase urinary pH to a level of 6.0 to 7.0. • Severe hypocitraturia (urinary citrate < 150 mg/day): therapy should be initiated at 60 mEq per day; a dose of 30 mEq two times per day or 20 mEq three times per day with meals or within 30 minutes after meals or bedtime snack (2.2)
  • • Mild to moderate hypocitraturia (urinary citrate >150 mg/day): therapy should be initiated at 30 mEq per day; a dose of 15 mEq two times per day or 10 mEq three times per day with meals or within 30 minutes after meals or bedtime snack (2.3)
2.1 Dosing Instructions

2.1 Dosing Instructions Treatment with extended release potassium citrate should be added to a regimen that limits salt intake (avoidance of foods with high salt content and of added salt at the table) and encourages high fluid intake (urine volume should be at least two litres per day). The objective of treatment with potassium citrate extended-release tablets is to provide potassium citrate in sufficient dosage to restore normal urinary citrate (greater than 320 mg/day and as close to the normal mean of 640 mg/day as possible), and to increase urinary pH to a level of 6.0 or 7.0.

Monitor serum electrolytes (sodium, potassium, chloride and carbon dioxide), serum creatinine and complete blood counts every four months and more frequently in patients with cardiac disease, renal disease or acidosis. Perform electrocardiograms periodically. Treatment should be discontinued if there is hyperkalemia, a significant rise in serum creatinine or a significant fall in blood hematocrit or hemoglobin.

2.2 Severe Hypocitraturia

2.2 Severe Hypocitraturia In patients with severe hypocitraturia (urinary citrate < 150 mg/day), therapy should be initiated at a dosage of 60 mEq /day (30 mEq two times/day or 20 mEq three times/day with meals or within 30 minutes after meals or bedtime snack). Twenty-four hour urinary citrate and/or urinary pH measurements should be used to determine the adequacy of the initial dosage and to evaluate the effectiveness of any dosage change.

In addition, urinary citrate and/or pH should be measured every four months. Doses of potassium citrate extended-release tablets greater than 100 mEq/day have not been studied and should be avoided.

2.3 Mild to Moderate Hypocitraturia

2.3 Mild to Moderate Hypocitraturia In patients with mild to moderate hypocitraturia (urinary citrate > 150 mg/day) therapy should be initiated at 30 mEq/day (15 mEq two times/day or 10 mEq three times/day with meals or within 30 minutes after meals or bedtime snack). Twenty-four hour urinary citrate and/or urinary pH measurements should be used to determine the adequacy of the initial dosage and to evaluate the effectiveness of any dosage change.

Doses of Potassium citrate extended-release tablets greater than 100 mEq/day have not been studied and should be avoided.

Dosing: Altered kidney function

Potassium citrate is a urinary alkalinizer for stone prevention (hypocitraturia, renal tubular acidosis with stones, uric acid stones). Each 1,080 mg tablet supplies 10 mEq of potassium. The US label contraindicates it when GFR is below 0.7 mL/kg/min (about 35 mL/min at 50 kg) and in hyperkalemia and in conditions that predispose to it, including chronic renal failure, and stops it if serum creatinine rises significantly.

Kidney function measure: Label contraindication: GFR <0.7 mL/kg/min (about 35 mL/min at 50 kg, 49 mL/min at 70 kg), and any condition predisposing to hyperkalemia including chronic renal failure.

Show full dosing details
CrCl ≥60 mL/min
Severe hypocitraturia: start 60 mEq/day (30 mEq twice daily or 20 mEq three times daily) with meals; mild to moderate: start 30 mEq/day; avoid above 100 mEq/day (label). Check electrolytes, creatinine and blood count every 4 months.
CrCl 30–59 mL/min
Contraindicated when GFR is below 0.7 mL/kg/min (multiply by body weight: 50 kg = 35 mL/min; 70 kg = 49 mL/min) (label 4). Above that, use only with specialist input, potassium checks within 1 week of starting and of any dose change, and no potassium-sparing drugs. The label also says to avoid it in chronic renal failure and to stop it if creatinine rises significantly.
CrCl 15–29 mL/min
Contraindicated: GFR below 0.7 mL/kg/min, and hyperkalemia or conditions predisposing to it, including chronic renal failure (label 4, 5.1). Potentially fatal hyperkalemia can develop rapidly and silently.
CrCl <15 mL/min (not on dialysis)
Contraindicated: GFR below 0.7 mL/kg/min, and hyperkalemia or conditions predisposing to it, including chronic renal failure (label 4, 5.1). Potentially fatal hyperkalemia can develop rapidly and silently.
Hemodialysis (intermittent)
Contraindicated in hyperkalemia or conditions predisposing to it, including chronic renal failure; avoid in chronic renal failure (label 4, 5.1). Potentially fatal hyperkalemia can develop rapidly and silently.
Peritoneal dialysis
Contraindicated in hyperkalemia or conditions predisposing to it, including chronic renal failure; avoid in chronic renal failure (label 4, 5.1). Potentially fatal hyperkalemia can develop rapidly and silently.
CRRT
Contraindicated: acute kidney injury and acute dehydration predispose to hyperkalemia (label).
  • Dialyzable? Potassium is removed by dialysis (physiology; label lists hemodialysis and peritoneal dialysis among hyperkalemia treatments).
  • Monitoring Serum potassium, sodium, chloride, carbon dioxide, creatinine and complete blood count every 4 months; more often with heart or kidney disease or acidosis. Periodic ECG. Urinary citrate and pH. Stop for hyperkalemia, significant creatinine rise or fall in hemoglobin (label).
Children (kidney dosing)
eGFR ≥60
Not approved for children; kidney dosing not applicable.
eGFR 30–59
Not approved for children; kidney dosing not applicable.
eGFR 15–29
Not approved for children; kidney dosing not applicable.
eGFR <15 (not on dialysis)
Not approved for children; kidney dosing not applicable.
Hemodialysis (intermittent)
Not approved for children; kidney dosing not applicable.
Peritoneal dialysis
Not approved for children; kidney dosing not applicable.
CRRT
Not approved for children; kidney dosing not applicable.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

US label text: Dosage and administration (renal excerpts) US FDA label

Monitor serum electrolytes (sodium, potassium, chloride and carbon dioxide), serum creatinine and complete blood counts every four months and more frequently in patients with cardiac disease, renal disease or acidosis.

Dosing: Pediatric

Approved ages
Safety and effectiveness in children not established (label).
Usual dose
Not established.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed
Pediatric use (US label) US FDA label

8.4 Pediatric Use Safety and effectiveness in children have not been established.

Dosage forms

Philippines

  • Extended-release tablet: 1080 mg
  • ) extended-release tablet: 1.08 g (10 mEq, 1.08 mg (10 mEq, 1.080 g (10 mEq, 1.080 mg (10 mEQ, 1.620 g (15 mEq, 1080 mg (10 mEq, 1620 mg (Eq. to 15 mEq
  • ): 1.080 g (10 mEq
  • ) prolonged-release tablet: 1080 mg (10 mEq
  • Extended-release: 1.620 g

Registered products in the Philippines

61 products registered with the Food and Drug Administration (FDA) Philippines list Potassium citrate as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products61
Philippine FDA-registered products for Potassium citrate
Package insert
AcaldinPotassium Citrate
1080 mg Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
Medchoice Endocrine Group, Inc.Importer: Ambica International Corporation
DRP-4840-09
Oct 17, 2028
AcalkaPotassium Citrate
1080 mg (10 mEq) Prolonged-Release TabletAlu/OPA/PVC Blister Pack x 10's Box 30's; Alu/OPA/PVC Blister Pack x 10's Box 40's; Alu/OPA/PVC Blister Pack x 10's Box 100's
RxVAT-exempt
Ferrer Internacional, S.A.Spain
Importer: Patriot Pharmaceuticals Corporation
DR-XY20542
Dec 17, 2029
AcitratePotassium Citrate
1080 mg Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
Scriptmed, Inc.Importer: Ambica International Corporation
DRP-4840-01
Oct 17, 2028
Acitrate PlusPotassium citrate
1.620 g (15 mEq) Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
Scriptmed, Inc.Importer: Ambica International Corporation
DRP-14484-04
Sep 12, 2028
AlkacitPotassium Citrate
1080 mg Extended-Release TabletAlu/White PVC Blister Pack x 10’s (Box of 30's & Box of 100's))
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Healthlink 211 Pharma, Inc.Importer: Pharmakon Biotec Inc.
DRP-11044-08
Jan 18, 2027
AlkalinsePotassium Citrate (as Monohydrate)
1.08g (10 mEq) Extended-Release TabletAlu/Opaque White PVC Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
San Marino Laboratories CorporationPhilippines
—
DRP-2813
Jan 29, 2031
AlkasurePotassium Citrate
1080 mg Extended-Release TabletAlu/White PVC Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Alkem Laboratories CorporationImporter: Pharmakon Biotec Inc.
DRP-11044-07
Jan 18, 2027
AlkatratePotassium Citrate
1.08 g (10 mEq) Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Euroasia Pharmaceuticals, Inc.Importer: Pharmakon Biotec Inc.
DRP-13985-01
May 31, 2028
AzentratePotassium Citrate
1080 mg Extended-Release TabletAlu/White PVC Blister Pack x 10’s (Box of 100’s)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Kodapharm Med Corp.Importer: Pharmakon Biotec Inc.
DRP-11044-05
Jan 18, 2027
Aztrate XRPotassium Citrate
1080 mg Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
A-Z Market Enterprise Developers Inc.Importer: Ambica International Corporation
DRP-4840-14
Oct 17, 2028
Aztrate XR PlusPotassium Citrate
1.620 g (15 mEq) Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
A-Z Market Enterprise Developers Inc.Importer: Ambica International Corporation
DRP-14484-02
Sep 12, 2028
CaltaPotassium citrate
1.620 g (15 mEq) Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
The Cathay YSS Distributors Co., Inc.Importer: Ambica International Corporation
DRP-14484-03
Sep 12, 2028
CaltaPotassium Citrate
1080 mg Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
The Cathay YSS Distributors Co., Inc.Importer: Ambica International Corporation
DRP-4840-18
Oct 17, 2028
CitrafluxPotassium Citrate
1.08 g (10 mEq) Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Rule Med Pharma Corp.Importer: Pharmakon Biotec, Inc.
DRP-13985-02
May 31, 2028
CitraposPotassium Citrate
1080 mg Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
Corbridge Group Phils. Inc.Importer: Ambica International Corporation
DRP-4840-11
Oct 17, 2028
Citrapos XRPotassium citrate
1.620 g (15 mEq) Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
Corbridge Group Phils., Inc.Importer: Ambica International Corporation
DRP-14484-01
Sep 12, 2028
CytrakonPotassium Citrate
1080 mg Extended Release TabletAlu/White PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
MAGBRO HEALTHCARE PVT. LTD.India
Pharmakon Biotec Inc.
DRP-11044
Jan 18, 2027
D-lithPotassium Citrate
1080 mg Extended-Release TabletAlu / White PVC Blister Pack x 10's (Box of 30's & 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Labmate Pharma Inc.Importer: Pharmakon Biotec Inc.
DRP-11044-15
Jan 18, 2027
FaracitPotassium Citrate
1.08g (10 mEq) Extended-Release TabletAlu/Alu Blister Pack X 10'S (Box Of 30'S)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Pharmakon Biotec, Inc.
DRP-13985
May 31, 2028
GitratePotassium Citrate
1080 mg Extended-Release TabletAlu/White PVC Blister Pack x 10’s (Box of 100’s)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Gijun Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-11044-04
Jan 18, 2027
K-CitrizPotassium Citrate
1080 mg Extended-Release TabletAlu/White PVC Blister Pack x 10's (Box of 30's and Box of 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-11044-06
Jan 18, 2027
K-XRPotassium Citrate
1080 mg Extended-Release TabletAlu/White PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Littman Drug CorporationImporter: Pharmakon Biotec Inc.
DRP-11044-01
Jan 18, 2027
K-XRPotassium Citrate
1080 mg Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
Littman Drug CorporationImporter: Ambica International Corporation
DRP-4840-05
Oct 17, 2028
KaitratePotassium Citrate
1080 mg Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's and 90's)
RxVAT-exempt
Cooper Pharma LimitedIndia
Genace Pharma DistributorImporter: Ambica International Corporation
DRP-4840
Oct 17, 2028
KalcicurePotassium Citrate
1080 mg Extended-Release TabletAlu/White PVC Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-11044-13
Jan 18, 2027
Kc-TrolPotassium Citrate (as monohydrate)
1.08 mg (10 mEq) Extended-Release TabletAlu/Alu Blister Pack x 10’s (Box of 100's)
RxVAT-exempt
Globela Pharma Pvt. Ltd.India
AMB HK ENTERPRISES INC.
DRP-19021
Oct 19, 2031
KelcitraPotassium Citrate
1080 mg Extended-Release TabletAlu/White PVC Blister Pack x 10’s (Box of 100’s); Alu/White PVC Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Ellebasy Medicale TradingImporter: Pharmakon Biotec Inc.
DRP-11044-03
Jan 18, 2027
KeltasyPotassium Citrate
1080 mg Extended-Release TabletAlu/White PVC Blister Pack x 10’s (Box of 30's & Box of 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Ellebasy Medicale Group Inc.Importer: Pharmakon Biotec Inc.
DRP-11044-11
Jan 18, 2027
KeltiqoPotassium Citrate
1080 mg Extended-Release TabletAlu / White PVC Blister Pack x 10’s (Box of 30's and 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Amediqo Phils., Inc.Importer: Pharmakon Biotec Inc.
DRP-11044-09
Jan 18, 2027
KycitratePotassium citrate
1.620 g (15 mEq) Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
Ambica International Corporation.Importer: Ambica International Corporation
DRP-14484
Sep 12, 2028
LithrocalPotassium Citrate
1080 mg Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
Distribution Solutions Phils., Inc.Importer: Ambica International Corporation
DRP-4840-03
Oct 17, 2028
MedcitPotassium Citrate (as monohydrate)
1.080 g (10 mEq) Extended-Release TabletHDPE Plastic Bottle x 30's (Box of 1's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Ultramed Pharma, Inc.
DR-XY42469
Aug 29, 2028
MedcitPotassium Citrate (as monohydrate)
1.080 g (10 mEq) Extended-Release TabletHDPE Plastic Bottle x 30's (Box of 1's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Ultramed Pharma, Inc.
DRP-13375
Aug 29, 2028
NonePotassium Citrate
1080 mg Extended-Release TabletAlu/White PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Reta DrugImporter: Pharmakon Biotec Inc.
DRP-11044-14
Jan 18, 2027
NonePotassium Citrate
1080 mg Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
Diafarm Inc.Importer: Ambica International Corporation
DRP-4840-02
Oct 17, 2028
NonePotassium Citrate
1080 mg Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
Ritemed Phils., Inc.Importer: Ambica International Corporation
DRP-4840-10
Oct 17, 2028
NonePotassium Citrate
1080 mg Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
TGP Pharma, Inc.Importer: Ambica International Corporation
DRP-4840-12
Oct 17, 2028
NonePotassium Citrate
1080 mg Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
Actimed, Inc.Importer: Ambica International Corporation
DRP-4840-13
Oct 17, 2028
NostonPotassium Citrate
1.080 g (10 mEq) Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Nucare Labs LLPIndia
ECE Pharmaceuticals, Inc.Importer: Biophil Medical Equipment and Supplies Trading
DRP-15965
Oct 4, 2029
NostonPotassium Citrate
1.620 g Extended-ReleaseAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Nucare Labs LLPIndia
ECE Pharmaceuticals, Inc.Importer: Biophil Medical Equipment and Supplies Trading
DRP-15846
Sep 20, 2029
PhroletsPotassium Citrate
1080 mg Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
Guimhealth Pharmaceutical Distributor and DrugstoreImporter: Ambica International Corporation
DRP-4840-15
Oct 17, 2028
PocitPotassium Citrate (as monohydrate)
1.08g (10 mEq) Extended-Release TabletAlu/Opaque White PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
San Marino Laboratories CorporationCavite
Healthlink211 Pharma, Inc.
DRP-2813-03
Jan 29, 2031
PoratePotassium Citrate
1.080 g (10 mEq) Extended Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Flourish PharmaIndia
Speed Med Pharmaceuticals, Inc.Importer: Biophil Medical Equipment and Supplies Trading
DRP-16714
Jul 1, 2030
PoscifixPotassium Citrate
1080 mg Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-4840-06
Oct 17, 2028
PoscitcurePotassium Citrate
1080 mg Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation
DRP-4840-04
Oct 17, 2028
PositatePotassium Citrate
1080 mg Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
Macropharma CorporationImporter: Ambica International Corporation
DRP-4840-07
Oct 17, 2028
ProxytratePotassium citrate
1.620 g (15 mEq) Extended-Release TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Cooper Pharma LimitedIndia
TGP Pharma Inc.Importer: Ambica International Corporation
DRP-14484-05
Sep 12, 2028
RexcitratePotassium Citrate
1080 mg Extended-Release TabletAlu/White PVC Blister Pack x 10’s (Box of 100’s)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Rexmed Pharmaceutical SalesImporter: Pharmakon Biotec Inc.
DRP-11044-02
Jan 18, 2027
Saphreta-GE1080Potassium Citrate
1.080 g (10 mEq) Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Genom Biotech Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-18948
Oct 6, 2031
SaphtratePotassium Citrate
1.620 g (15 mEq) Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Genom Biotech Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-17401
Dec 19, 2030
SaphtratePotassium citrate
Extended-Release Tablet 1.080 g (10 mEq)Alu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-10252
Aug 23, 2036
SETHRATEPotassium Citrate
1.620 g (15 mEq) Extended-Release TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Genom Biotech Pvt. Ltd.India
777 RED PHARMA INC.Importer: Nelpa Lifesciences, Inc.
DRP-17401-01
Dec 19, 2030
TascitPotassium Citrate (as Monohydrate)
1080 mg (10 mEq) Extended-Release TabletFlex Foil Strip x 6's (Box of 30's); Flex Foil Strip x 4's (Box of 100's)
RxVAT-exempt
Amherst Laboratories, Inc.Philippines
Trader: Unilab, Inc.
DRP-9783
Dec 8, 2029
Tascit BIDPotassium Citrate
1620 mg (Eq. to 15 mEq) Extended Release TabletAlu Strip Foil x 4's (Box of 100's)
RxVAT-exempt
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, Inc.
DR-XY44622
Jun 8, 2031
TasiumatePotassium Citrate
1080 mg Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's and 90's)
RxVAT-exempt
Cooper Pharma LimitedIndia
One Pharma Marketing Inc.Importer: Ambica International Corporation
DRP-4840-17
Oct 17, 2028
TechtratePotassium Citrate
1080 mg Extended-Release TabletAlu/White PVC Blister Pack x 10’s (Box of 30's & Box of 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
One Technodrug Life Sciences Inc.Importer: Pharmakon Biotec Inc.
DRP-11044-10
Jan 18, 2027
UrecitPotassium Citrate
1080 mg Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cooper Pharma LimitedIndia
Metrophil Drug and Chemical TradingImporter: Ambica International Corporation
DRP-4840-08
Oct 17, 2028
UrineedPotassium Citrate
1080 mg Extended-Release TabletAlu/White PVC Blister Pack x 10’s (Box of 30's and 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Biocare Lifesciences, Inc.Importer: Pharmakon Biotec Inc.
DRP-11044-12
Jan 18, 2027
(no brand name)Potassium Citrate
1.080 mg (10 mEQ) Extended-Release TabletAlu/Alu Foil Strip x 4's (Box of 4's; 12's'; 16's; 32's; 40's; and 64's, and physician's sample Box of 4's)
RxVAT-exempt
Eskayef Pharmaceuticals LimitedIndia
AAA Pharma, Inc.
DR-XY49578
Nov 14, 2030
(no brand name)Potassium Citrate
1.08g (10mEq) Extended -Release TabletOff-White HDPE Bottle Sealed with Violet Plastic Cap x 15's, 30's, 60's and 90's (Box of 15's, 30's, 60's and 90's) (Physician Sample: Box of 5's)
RxVAT-exempt
Eskayef Pharmaceuticals LimitedBangladesh
ECE Pharmaceuticals, Inc.Importer: AAA Pharma, Inc.
DR-XY48514
Dec 1, 2027
(no brand name)Potassium Citrate
1080 mg (10 mEq) Extended Release TabletAlu/Alu Blister Pack x 10's (Box of 20's)
RxVAT-exempt
Eskayef Pharmaceuticals LimitedBangladesh
Firmlink Pharma Phils. Co.
DR-XY48582
Jan 25, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS • 5 mEq tablets are uncoated, pale yellow colored, round shaped, bi-convex, debossed with 'S406'on one side and plain on the other side. • 10 mEq tablets are uncoated, pale yellow colored, caplet shaped, bi-convex, debossed with 'S407'on one side and plain on the other side • 15 mEq tablets are uncoated, pale yellow colored, caplet shaped, bi-convex, debossed with 'S408'on one side and plain on the other side. Tablets: 5 mEq, 10 mEq and 15 mEq (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • • Hyperkalemia: In patients with impaired mechanisms for excreting potassium, potassium citrate administration can produce hyperkalemia and cardiac arrest. Potentially fatal hyperkalemia can develop rapidly and be asymptomatic. The use of potassium citrate in patients with chronic renal failure, or any other condition which impairs potassium excretion such as severe myocardial damage or heart failure, should be avoided (5.1)
  • • Gastrointestinal lesions: if there is severe vomiting, abdominal pain or gastrointestinal bleeding, potassium citrate should be discontinued immediately and the possibility of bowel perforation or obstruction investigated (5.2)
5.1 Hyperkalemia

5.1 Hyperkalemia In patients with impaired mechanisms for excreting potassium, potassium citrate administration can produce hyperkalemia and cardiac arrest. Potentially fatal hyperkalemia can develop rapidly and be asymptomatic. The use of potassium citrate in patients with chronic renal failure, or any other condition which impairs potassium excretion such as severe myocardial damage or heart failure, should be avoided.

Closely monitor for signs of hyperkalemia with periodic blood tests and ECGs.

5.2 Gastrointestinal Lesions

5.2 Gastrointestinal Lesions Solid dosage forms of potassium chlorides have produced stenotic and/or ulcerative lesions of the small bowel and deaths. These lesions are caused by a high local concentration of potassium ions in the region of the dissolving tablets, which injured the bowel. In addition, perhaps because wax-matrix preparations are not enteric-coated and release some of their potassium content in the stomach, there have been reports of upper gastrointestinal bleeding associated with these products.

The frequency of gastrointestinal lesions with wax-matrix potassium chloride products is estimated at one per 100,000 patient-years. Experience with potassium citrate is limited, but a similar frequency of gastrointestinal lesions should be anticipated. If there is severe vomiting, abdominal pain or gastrointestinal bleeding, potassium citrate should be discontinued immediately and the possibility of bowel perforation or obstruction investigated.

Drug interactions

Drug or classSeverityEffectWhat to do
Potassium-sparing diuretics (spironolactone, triamterene, amiloride)AvoidSevere hyperkalemia (label).Avoid.
ACE inhibitors, ARBs, NSAIDsAdjust or monitorHyperkalemia (label).Monitor potassium.
Anticholinergics and other drugs slowing gut transitAvoidMore gastrointestinal irritation (label).Avoid (contraindicated with anticholinergics).

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed
Drug interactions (US label) US FDA label
  • The following drug interactions may occur with potassium citrate: • Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1)
  • • Drugs that slow gastrointestinal transit time: These agents (such as anticholinergics) can be expected to increase the gastrointestinal irritation produced by potassium salts (7.2)
  • • Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia (7.3)
  • • Nonsteroidal Anti-inflammatory drugs (NSAIDs) monitor for hyperkalemia (7.4)
7.1 Potential Effects of Potassium

7.1 Potential Effects of Potassium Citrate on Other Drugs Potassium-sparing Diuretics: Concomitant administration of potassium citrate and a potassium-sparing diuretic (such as triamterene, spironolactone or amiloride) should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia.

7.2 Potential Effects of Other Drugs on Potassium

7.2 Potential Effects of Other Drugs on Potassium Citrate Drugs that slow gastrointestinal transit time: These agents (such as anticholinergics) can be expected to increase the gastrointestinal irritation produced by potassium salts.

7.3 Renin-Angiotensin-Aldosterone System Inhibitors

7.3 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy.

7.4 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

7.4 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostagladin E and impairing the renin-angiotensin system. Closely monitor potassium in patients on concomitant NSAIDs.

Adverse reactions

Common

  • Abdominal discomfort, nausea, vomiting, diarrhea

Serious

  • Hyperkalemia, cardiac arrest
  • Gastrointestinal ulceration, bleeding, obstruction
renalcarematters.com, reviewed
Adverse reactions (US label) US FDA label

6 ADVERSE REACTIONS Some patients may develop minor gastrointestinal complaints such as abdominal discomfort, vomiting, diarrhea, loose bowel movements or nausea. These may be alleviated by taking the dose with meals or snacks or by reducing the dosage (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Strides Pharma Inc. at 1-877-244-9825 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Postmarketing Experience Some patients may develop minor gastrointestinal complaints during potassium citrate therapy, such as abdominal discomfort, vomiting, diarrhea, loose bowel movements or nausea.

These symptoms are due to the irritation of the gastrointestinal tract, and may be alleviated by taking the dose with meals or snacks, or by reducing the dosage. Patients may find intact matrices in their feces.

Monitoring parameters

  • Serum potassium, sodium, chloride, carbon dioxide, creatinine and complete blood count every 4 months; more often with heart or kidney disease or acidosis. Periodic ECG. Urinary citrate and pH. Stop for hyperkalemia, significant creatinine rise or fall in hemoglobin (label). Kidney
  • Potassium, creatinine, electrolytes, blood count every 4 months
  • ECG periodically
renalcarematters.com, reviewed

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Animal reproduction studies have not been conducted. It is also not known whether potassium citrate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Potassium citrate should be given to a pregnant woman only if clearly needed.

Breastfeeding considerations

Lactation (US label) US FDA label

8.3 Nursing Mothers The normal potassium ion content of human milk is about 13 mEq/L. It is not known if potassium citrate has an effect on this content. Potassium citrate should be given to a woman who is breastfeeding only if clearly needed.

Mechanism of action

12.1 Mechanism of Action When potassium citrate is given orally, the metabolism of absorbed citrate produces an alkaline load. The induced alkaline load in turn increases urinary pH and raises urinary citrate by augmenting citrate clearance without measurably altering ultrafilterable serum citrate. Thus, potassium citrate therapy appears to increase urinary citrate principally by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate.

The increased filtered load of citrate may play some role, however, as in small comparisons of oral citrate and oral bicarbonate, citrate had a greater effect on urinary citrate. In addition to raising urinary pH and citrate, potassium citrate increases urinary potassium by approximately the amount contained in the medication.

In some patients, potassium citrate causes a transient reduction in urinary calcium. The changes induced by potassium citrate produce urine that is less conducive to the crystallization of stone-forming salts (calcium oxalate, calcium phosphate and uric acid). Increased citrate in the urine, by complexing with calcium, decreases calcium ion activity and thus the saturation of calcium oxalate.

Citrate also inhibits the spontaneous nucleation of calcium oxalate and calcium phosphate (brushite). The increase in urinary pH also decreases calcium ion activity by increasing calcium complexation to dissociated anions. The rise in urinary pH also increases the ionization of uric acid to the more soluble urate ion. Potassium citrate therapy does not alter the urinary saturation of calcium phosphate, since the effect of increased citrate complexation of calcium is opposed by the rise in pH-dependent dissociation of phosphate.

Calcium phosphate stones are more stable in alkaline urine. In the setting of normal renal function, the rise in urinary citrate following a single dose begins by the first hour and lasts for 12 hours. With multiple doses the rise in citrate excretion reaches its peak by the third day and averts the normally wide circadian fluctuation in urinary citrate, thus maintaining urinary citrate at a higher, more constant level throughout the day.

When the treatment is withdrawn, urinary citrate begins to decline toward the pre-treatment level on the first day. The rise in citrate excretion is directly dependent on the potassium citrate dosage. Following long-term treatment, potassium citrate at a dosage of 60 mEq/day raises urinary citrate by approximately 400 mg/day and increases urinary pH by approximately 0.7 units.

In patients with severe renal tubular acidosis or chronic diarrheal syndrome where urinary citrate may be very low (<100 mg/day), potassium citrate may be relatively ineffective in raising urinary citrate. A higher dose of potassium citrate may therefore be required to produce a satisfactory citraturic response. In patients with renal tubular acidosis in whom urinary pH may be high, potassium citrate produces a relatively small rise in urinary pH.

US FDA label

Pharmacokinetics

Key PK parameters

OnsetUrinary citrate rises within 1 hour; lasts about 12 hours
Metabolism (CYP, transporters)Citrate metabolized to bicarbonate
Renal excretion kidneyPotassium excreted by the kidney
Dialyzability kidneyPotassium removed by dialysis
renalcarematters.com, reviewed
Half-life and elimination (verbatim, US label)

The induced alkaline load in turn increases urinary pH and raises urinary citrate by augmenting citrate clearance without measurably altering ultrafilterable serum citrate.

Thus, potassium citrate therapy appears to increase urinary citrate principally by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate.

The increased filtered load of citrate may play some role, however, as in small comparisons of oral citrate and oral bicarbonate, citrate had a greater effect on urinary citrate.

In addition to raising urinary pH and citrate, potassium citrate increases urinary potassium by approximately the amount contained in the medication.

In some patients, potassium citrate causes a transient reduction in urinary calcium.

Pharmacokinetics (US label) US FDA label

12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action When potassium citrate is given orally, the metabolism of absorbed citrate produces an alkaline load. The induced alkaline load in turn increases urinary pH and raises urinary citrate by augmenting citrate clearance without measurably altering ultrafilterable serum citrate.

Thus, potassium citrate therapy appears to increase urinary citrate principally by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. The increased filtered load of citrate may play some role, however, as in small comparisons of oral citrate and oral bicarbonate, citrate had a greater effect on urinary citrate.

In addition to raising urinary pH and citrate, potassium citrate increases urinary potassium by approximately the amount contained in the medication. In some patients, potassium citrate causes a transient reduction in urinary calcium. The changes induced by potassium citrate produce urine that is less conducive to the crystallization of stone-forming salts (calcium oxalate, calcium phosphate and uric acid).

Increased citrate in the urine, by complexing with calcium, decreases calcium ion activity and thus the saturation of calcium oxalate. Citrate also inhibits the spontaneous nucleation of calcium oxalate and calcium phosphate (brushite). The increase in urinary pH also decreases calcium ion activity by increasing calcium complexation to dissociated anions.

The rise in urinary pH also increases the ionization of uric acid to the more soluble urate ion. Potassium citrate therapy does not alter the urinary saturation of calcium phosphate, since the effect of increased citrate complexation of calcium is opposed by the rise in pH-dependent dissociation of phosphate. Calcium phosphate stones are more stable in alkaline urine.

In the setting of normal renal function, the rise in urinary citrate following a single dose begins by the first hour and lasts for 12 hours. With multiple doses the rise in citrate excretion reaches its peak by the third day and averts the normally wide circadian fluctuation in urinary citrate, thus maintaining urinary citrate at a higher, more constant level throughout the day.

When the treatment is withdrawn, urinary citrate begins to decline toward the pre-treatment level on the first day. The rise in citrate excretion is directly dependent on the potassium citrate dosage. Following long-term treatment, potassium citrate at a dosage of 60 mEq/day raises urinary citrate by approximately 400 mg/day and increases urinary pH by approximately 0.7 units.

In patients with severe renal tubular acidosis or chronic diarrheal syndrome where urinary citrate may be very low (<100 mg/day), potassium citrate may be relatively ineffective in raising urinary citrate. A higher dose of potassium citrate may therefore be required to produce a satisfactory citraturic response. In patients with renal tubular acidosis in whom urinary pH may be high, potassium citrate produces a relatively small rise in urinary pH.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Potassium Citrate 10 mEq Tablet₱4.71–₱11.00Reference ₱6.80per tabletDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Potassium (as citrate)
PNF listingOral: 1080 mg (10 mEq) tablet
PNF listingOral: 1620 mg (15 mEq) extended release (ER) tablet)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. POTASSIUM CITRATE EXTENDED RELEASE · Strides Pharma Inc. [US FDA-approved label, version 10, July 1, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f38b02c-703c-4fc2-b833-654e41bd617f
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
  5. Strides Pharma Inc. (2025). Potassium citrate extended-release tablets [Prescribing information; US FDA-approved label, ANDA206813, set ID 5f38b02c-703c-4fc2-b833-654e41bd617f, version effective July 1, 2025]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f38b02c-703c-4fc2-b833-654e41bd617f

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .